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Preface 
The Uses of Penicillin and Streptomycin con-
sists of the three Porter Lectures delivered under 
the auspices of the University of Kansas School of 
Medicine. I am informed that Dr. }. L. Porter 
came to Kansas from Ohio in i868 ? just two years 
after the founding of the University. After gradu-
ating from Rush Medical College in 1881, he re-
turned to Kansas, where he practiced medicine 
until his death. During his lifetime, Dr. Porter 
had an opportunity to follow the rapid growth 
and development of medical science in this coun-
try. His interest in scholarship and in medical re-
search led to his establishing the lectureship which 
bears his name. 
I wish to express to the Committee on the 
Porter Lectures my sincere appreciation for the 
honor of giving them. 
Chester S. Keefer, M. D. 
Boston, 1949 
I. 
I. 
P e n i c i l l i n in Medical and Surgical 
P r a c t i c e 
D o u b t l e s s no therapeutic agent has 
caused m o r e discussion than penicillin. No other anti-
i i i f ective a g e n t has been used so widely with such success-
fu l results i n so many different diseases. It was only six 
years ago t h a t the first patient was treated adequately 
w i t h penici l l in in the United States. It is impossible to 
assess complete ly the benefits that have flowed from 
t h e discovery and development of penicillin.|STthe be-
ginning of o u r discussion it is well to say something about 
t h e dosage forms of penicillin that are available for clin-
i c a l use. 
DOSAGE FORMS FOR USE IN TREATMENT OF SYSTEMIC 
INFECTIONS 
Amorphous Penicillin. Amorphous penicillin is now 
u s e d less a n d less, because it is a mixture of penicillins. 
T h a t is to say, it contains penicillin G-K-F. Penicillin G 
is the p r o d u c t about which we have the greatest amount 
of information and which we know is highly effective. In 
s p i t e of t h e fact that many samples of amorphous peni-
c i l l in were found to contain at least 85 per cent penicillin 
G> it b e c a m e unpopular as an agent for the treatment of 
a l l infections because it was shown that penicillin K was 
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relatively ineffective in the treatment of experimental 
syphilis, and less effective than penicillin G in the treat-
ment of experimental streptococcic and pneumococcic 
infection in mice. At present, there are some prepara-
tions of amorphous calcium penicillin in penicillin in oil 
and wax or amorphous aluminum penicillin in oil, avail-
able for use, but very little amorphous penicillin is now 
available for use in aqueous preparations. 
Crystalline Penicillin G. This is the most widely used 
preparation parenterally and orally. The crystals are dis-
pensed in aqueous solutions, or suspended in peanut oil 
and wax, for parenteral use. They are combined with 
buffers in tablets for oral use, and combined with oint-
ments for topical use. 
Salts of Penicillin. There are two commonly used 
salts of penicillin, the sodium and the potassium. They 
are both soluble and active, and there is no choice be-
tween the two salts in so far as therapeutic results are 
concerned. Recently a new salt has been prepared, pro-
caine salt of benzyl penicillin. This salt is soluble in 0.7 
per cent solution and contains approximately 50 per cent 
procaine. It is suspended in sesame oil and is used intra-
muscularly. It is absorbed slowly, so that in many pa-
tients penicillin is found in the blood for as long as 
thirty-six to forty-eight hours following a single injection 
of 300,000 units. Also, aluminum stearate has been used 
as an agent along with peanut oil to delay the absorption 
of potassium penicillin G. 
Oral Penicillin. The ideal way to give any drug is by 
mouth. It is now established that penicillin can be ab-
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sorbed from the gastrointestinal tract, but given by 
mouth about five times as much penicillin is required to 
obtain plasma concentrations comparable to those ob-
tained when penicillin is given by the intramuscular 
route. That penicillin is effective by the oral route has 
been repeatedly demonstrated by many observers. One 
of the drawbacks to its more widespread use has been its 
cost. 
Aerosol Penicillin. Crystalline penicillin G, dissolved 
in physiological salt solution, is used as an aerosol for the 
treatment of bronchopulmonary disease or chronic para-
nasal sinusitis. Two hundred thousand to 1,000,000 units 
may be used daily for aerosol treatment. The solutions 
are passed through a DeVilbiss No. 40 or a vaponephrin 
nebulizer, a hand bulb or a constant pressure of oxygen 
flowing at the rate of 6 liters a minute being used. 
Penicillin in Ointments. Ointments for the local or 
topical application of penicillin are available for use in 
the conjunctivae or on the skin. They are stable and use-
ful for the treatment of infections locally. They should 
be used sparingly and for a brief period of time, since 
sensitization may arise following the use of penicillin in 
this way much more often than when it is taken orally 
or given parenterally. 
DOSAGE 
An adequate dose of penicillin might be defined as 
that amount that will cure the patient with a susceptible 
infection, in the shortest period of time, and eliminate 
the infecting organisms from the body. Since there are 
so many variables in the treatment of any specific infec-
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t i o n in man it is extremely difficult to make any categori-
ca l rules concerning dosage in a given infection. It is 
impor tant , nevertheless, to develop the best methods of 
t r e a t m e n t with penicillin so that optimum results may 
b e obtained with the least discomfort and expense to the 
pat ient . One of the greatest difficulties that face us in 
a t tempt ing to assess dosage of penicillin is the fact that 
i t is a nontoxic drug. That is to say, very large amounts 
of penicillin can be given for long periods of time with-
o u t producing any signs of intoxication. When any drug 
is nontoxic , it is difficult to determine the minimum-
effect dose, because the temptation is great to give larger 
a m o u n t s of the drug than are necessary for producing 
a favorable clinical result. 
Other factors of importance in dosage are the type of 
infect ion, and its location. Everyone knows that penicil-
l i n is an agent that inhibits the growth of a wide variety 
of bacteria, but different species of bacteria vary enor-
m o u s l y in their resistance to the action of the drug. In 
fact , different strains of organisms within a species will 
o f ten vary in their susceptibility to penicillin. AH these 
factors make it difficult to define the minimum effective 
d o s e for each infection. In spite of the difficulties in-
v o l v e d , it is well to review some of the information con-
c e r n e d with ( i ) the mode of action of penicillin, (2) the 
effective plasma concentrations that inhibit the growth 
of organisms, and (3) the time-dose relationships. 
Mechanism of Action of Penicillin. Speaking broadly, 
penic i l l in is both bacteriostatic and bactericidal. The 
destruct ive power of penicillin in vitio and probably in 
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vivo is greatest during the period when the bacteria are 
multiplying rapidly. It has been demonstrated in vitro 
that the greatest number of organisms are killed during 
the first five to eight hours after exposure to penicillin. 
The organisms that survive this initial period may not be 
killed for twenty-four to thirty-six hours in spite of the 
fact that they are exposed to the continuing action of 
penicillin. When the organisms that survive the five- or 
eight-hour period are removed from the environment 
of penicillin and re-inoculated into fresh broth without 
penicillin, it is found that their lag period is slightly pro-
longed, but once they start to reproduce, they are highly 
susceptible once more to the action of penicillin. From 
such in vitro observations, it has been suggested that pen-
icillin must be maintained at a minimal effective con-
centration for a sufficiently long period of time, so that 
all organisms are destroyed and their reproduction pre-
vented. 
It has been suggested further that recovery from a 
given infection in man will occur once the minimum 
concentration of penicillin is maintained in the blood 
and tissues for a sufficient period of time to kill off large 
numbers of organisms and to prevent their reproduction. 
When the minimum effective concentration necessary 
to produce a remission is not maintained for a much 
longer period of time than that necessary to reduce the 
total number of organisms, then relapse will occur. Both 
the concentration of penicillin and the time of exposure 
of the organisms are important. It would appear that the 
total tithe organisms are exposed to minimum effective 
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concentrations of penicillin is more important than the 
exposure of organisms to high concentrations of penicil-
lin for a short period of time alternating with penicillin-
free periods. There are good reasons for believing that the 
minimum effective level in man need not be continuous 
through the 24-hour period in order to bring about re-
covery from infection, but the minimum effective con-
centration must be maintained for a sufficiently long 
period of time for the organisms to be destroyed or pre-
vented from entering a phase of active growth once again. 
This statement naturally raises two questions: ( 1 ) What 
is a minimum effective level and (2) what is the time-
interval between intramuscular injections in man that is 
required in order to obtain the optimum results? 
Minimum Effective Plasma and Tissue Concentra-
tions of Penicillin. Let us now turn our attention briefly 
to the question of the minimum effective level of penicil-
lin in the blood and tissues. Theoretically this minimum 
effective level would be the amount that would cause 
complete inhibition of the growth of organisms and their 
destruction. The determination of minimum effective 
levels of penicillin that will kill organisms in the test tube 
is much easier than the determination of the minimal 
effective plasma and tissue concentrations in the human 
body. Moreover, it is widely recognized that one cannot 
in every instance transfer in vitro activity to in vivo con-
ditions with penicillin. Nevertheless, the sensitivity of a 
given organism to penicillin gives one a rough approxi-
mation of the effective concentrations of penicillin that 
will be needed to inhibit the growth of organisms at the 
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site of the infection. The plasma concentrations of peni-
cillin can be determined readily. The concentration of 
penicillin in the tissues may be more difficult to ascertain. 
W e know, however, that considerable differences exist 
between plasma and tissue concentrations. 
In general, it has been shown that the concentration 
of penicillin which can be delivered to the tissues (except 
in the case of spinal fluid, organized thromboses, ab-
scesses) is between 10 and 50 per cent of that in the 
plasma. Therefore, for any desired concentration in the 
tissues, it would be well to maintain a concentration of 
penicillin two to ten times that in the circulating blood. 
As an example, one could say that if the sensitivity of an 
organism in vitro was .02 unit per milliliter, then it would 
be desirable to maintain a plasma concentration of .04 or 
.2 unit per milliliter in order for the tissue concentration 
to be approximately .02 unit. While this is perhaps some-
what theoretical, it as least gives one a rough guide to the 
minimum effective level of penicillin in blood and tis-
sues. 
It can be said, then, that the minimum effective 
plasma and tissue concentration should be at least two 
to ten times the amount of penicillin that will produce 
a bactericidal effect against the organism in vitro. 
From this discussion of dosage so far, you probably 
have gathered that the therapeutic activity of a given 
dose of penicillin will depend upon the amount that is 
given and the total length of time that penicillin remains 
at the maximum bactericidal level in the blood and tis-
sues plus the time required for the organisms to recover 
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from penicillin and begin multiplication. W e know from 
experience that it is unnecessary to maintain the concen-
tration of penicillin in the blood and tissues continuously 
at the maximum bactericidal level in order to attain re-
covery. But the truth of the matter is that the optimum 
time-dose relationships have not been worked out for all 
infections, and we do not know whether the present-day 
results can be improved by changing time-dose relation-
ships or not. 
Time-Dose Relationships. There are two points of 
view concerning time-dose schedules of penicillin: ( i ) 
intermittent treatment, so spaced that there are periods 
of effective plasma concentrations separated by penicil-
lin-free intervals; (2) intermittent or continuous injec-
tions of penicillin that will maintain an effective bacteri-
cidal plasma concentration for a sufficient period of time 
to inhibit completely the growth of organisms, plus the 
time required for the organisms to recover from the drug 
and effectively resume multiplication. In other words, 
one point of view is that penicillin should be present in 
the blood continuously, or at least for prolonged periods 
of time, and the other view is that penicillin need be 
present in the blood only intermittently. The difficulty in 
deciding how often and how much penicillin should be 
given resolves itself into determining what an effective 
plasma concentration should be and how long a period 
may elapse between injections before bacteria will begin 
to grow once again and cause relapse. Only experience 
and experiments with various infections can provide the 
answers for all infections. 
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In our own clinic, Dr. Weinstein has demonstrated 
that following the use of 100,000 units of penicillin every 
eight hours in children, penicillin is found in the blood 
for only two hours after injection, i.e., six hours out of the 
24-hour period; and that streptococci disappear from the 
local lesions promptly within twenty-four to forty-eight 
hours. Moreover, following the use of 300,000 units of 
penicillin by mouth every eight hours, similar good re-
sults were obtained, but penicillin was detected in the 
blood for a longer period of time, i.e., for six hours after 
each injection. 
It seems plain, therefore, that in the treatment of 
hemolytic streptococcic infections in children periods of 
effective concentrations separated by penicillin-free inter-
vals are in fact as effective as continuously maintained 
levels. 
In gonococcic infections, we know that 98 per cent of 
patients can be cured with a single injection of 300,000 
units of penicillin in oil and wax or with 50,000 units 
given in aqueous solution every three hours for three 
doses (total dosage, 150,000 units). W e have some evi-
dence that as little as 17,500 units of procaine penicillin 
in oil is sufficient to cure 98 per cent of patients with 
gonorrhea. 
For pneumococcic lobar pneumonia, it has been 
shown that 100,000 units given three times a day or 
200,000 or 300,000 units given twice a day is sufficient for 
curing 95 per cent of patients. 
One of the reasons that there are such wide variations 
in the time-dose schedules is that in most infections more 
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penicillin is given than is necessary to obtain e x c e l l e n t 
results. 
In summing up the question of dosage, then, i t can 
be said that the decision concerning the total d a i l y dose 
of penicillin and the time-interval between i n j e c t i o n s 
will depend upon the type and location of the i n f e c t i o n , 
the selection of the dosage form (i.e., oral, aqueous solu-
tion, penicillin in oil and wax, or procaine p e n i c i l l i n in 
oil), and most important of all the response of t h e pa-
tient to treatment. 
W e know that penicillin has been beneficial i n m a n y 
infections when it is given by constant i n t r a v e n o u s or 
intramuscular injection or when it is injected e v e r y t w o , 
three, or four hours. W e know further that p e n i c i l l i n in 
oil and wax has been effective when given o n c e d a i l y . 
Moreover, when penicillin is given by mouth e v e r y two 
or three hours in an amount three to five t i m e s that 
which is given parenterally, it is effective. Recent ly i t has 
been shown that patients with lobar pneumonia m a y re-
cover on either 200,000 or 300,000 units in aqueous solu-
tion given twice daily or following 100,000 units e v e r y 
eight hours. These observations certainly suggest t h a t it 
is unnecessary to have penicillin present in the t i s s u e s 
constantly in order to obtain favorable results. 
The final decision concerning dosage must r e s t w i t h 
the physician who is observing the response of t h e pa-
tient. The trend of treatment has been to i n c r e a s e the 
amount of penicillin that is given by individual i n j e c -
tion and to lengthen the time-interval between i n j e c -
tions. 
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REACTIONS TO PENICILLIN 
One of the extraordinary features about penicillin is 
that it is a nontoxic drug. Reactions due to the action of 
penicillin upon tissues are exceedingly rare. When exces-
sive amounts of penicillin are injected into the subarach-
noid space, convulsions are likely to occur. With the 
use of therapeutic doses, i.e., less than 50,000 units per 
injection, convulsions are very rare indeed; in our own 
experience we have never seen such a reaction. 
The common forms of reaction are due to hypersensi-
tivity to the penicillin itself. Following intramuscular in-
jection, the types of reaction that are observed in 1.5 to 5 
per cent of patients consist of fever, skin eruptions, 
edema of the skin and subcutaneous tissues, arthralgias. 
These reactions, which resemble serum sickness in clin-
ical features, may last from one to three weeks. They 
cause extreme discomfort from itching and burning of 
the skin, and sometimes from pains in the joints. In gen-
eral, it is desirable to discontinue the penicillin and to 
treat the disorders with benadryl or pyribenzamine, small 
doses of epinephrine if necessary, and the local applica-
tion of lotions for the relief of itching. 
Sensitization may also follow the local application of 
ointments, either ophthalmic ointments or ointments for 
dermatoses. This type of sensitization is more frequent 
than that following the parenteral use of penicillin. 
Contact dermatitis occurs in nurses and physicians 
who handle or prepare penicillin solutions. It is desirable, 
therefore, for all persons who frequently handle penicil-
lin to wear rubber gloves while preparing solutions and to 
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wash all penicillin from the gloves before removing them. 
Sensitization may also follow the use of aerosol solu-
tions or the use of troches for local infections of the 
mouth. Penicillin has caused sensitization after its use in 
tooth paste. 
Once a patient has become sensitized, he will react 
to a second injection of penicillin for a long period of 
time, i.e., a year or longer. It is well, therefore, to proceed 
with great care if it becomes necessary to use penicillin a 
second time. It has been possible to build up a tolerance 
to penicillin once a patient has become sensitized by giv-
ing small doses such as 1000 units at intervals of a day or 
more. On the whole, however, one must proceed cau-
tiously. 
Sensitization following the injection of penicillin in 
oil and wax has been reported somewhat more often than 
for aqueous penicillin, so that this must be taken into 
account when the preparation is used. In general, it has 
never occurred in more than 5 or 7 per cent of the cases. 
BACTERIAL RESISTANCE 
It is now well established that prolonged and re-
peated exposure of various bacteria to penicillin in vitro 
will select certain organisms that are increasingly resis-
tant to its action. Some strains of staphylococci are highly 
resistant to penicillin before they are ever exposed to it. 
Other resistant strains emerge during treatment of pa-
tients. It is a curious fact that resistant strains of gono-
cocci, pneumococci, and group A hemolytic streptococci 
have not been encountered in human infections. There 
have been some strains of nonhemolytic streptococci that 
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are naturally resistant to penicillin or become more resis-
tant following treatment. In general, however, penicillin 
failures have not been due to resistant organisms. The 
widespread use of penicillin has not led to the production 
of a large number of penicillin-resistant organisms. The 
risk of producing such strains seems to be minimal. 
SOME RESULTS OF PENICILLIN 
W e can now turn our attention to some of the re-
sults that have emerged from the use of penicillin in 
medicine and surgery. 
Meningitis. Sulfadiazine continues to be the drug of 
choice for the treatment of meningococcic meningitis. 
Penicillin should be used in these cases only after sulfa-
diazine has failed to bring the disease under control 
within forty-eight hours. When penicillin is used, both 
the intramuscular and the intrathecal route should be 
employed. 
In the treatment of pneumococcic, hemolytic strep-
tococcic, and staphylococcic meningitis, penicillin and 
sulfadiazine should both be used. Sulfadiazine by mouth 
and penicillin intramuscularly and intrathecally should 
be given to all patients with these forms of meningitis. 
There is some difference of opinion concerning the 
advisability of giving penicillin intrathecally for patients 
with any form of meningitis. In the first place, it is known 
that very little penicillin diffuses into the cerebral spinal 
fluid even when meningitis is present and when large 
amounts are given parenterally. It is also recognized that 
a certain number of patients with bacterial meningitis 
recover when penicillin is given only parenterally. 
13 
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In our own experience, however, and in the expe-
rience reported to the Committee on Chemotherapy dur-
ing the study program, the recovery rate was higher in 
those patients who received penicillin intramuscularly 
and intrathecally. Moreover, it has been shown that 
better results are obtained from both penicillin and sulfa-
diazine than when either one is given alone. 
Lung Abscess and Bronchiectasis. In acute lung ab-
scess, due to organisms that are susceptible to penicillin 
(staphylococcus, hemolytic streptococcus, spirochetal in-
fection), the results of penicillin treatment have been 
excellent. Early treatment and postural drainage are im-
portant. When the abscess is due to Klebsiella pneu-
moniae, streptomycin is the drug of choice; and when the 
organisms are mixed, then both penicillin and strepto-
mycin should be used together. 
Bronchiectasis and Chronic Bronchitis. The results of 
penicillin treatment in bronchiectasis have been pallia-
tive and not curative. Aerosol inhalations in amounts of 
150,000 to 500,000 to 1,000,000 units daily have been 
adequate for the control of a number of the acute exacer-
bations of infection. The sputum decreases in amount 
and the cough in frequency. One feature that is likely to 
be striking is the disappearance of penicillin-sensitive or-
ganisms and the predominance of gram-negative bacilli of 
the coli-aerogenes group. In some instances, it is well to 
use streptomycin as well as penicillin in the aerosol solu-
tions in an attempt to eliminate gram-negative as well as 
gram-positive bacteria from sputum cultures. 
Crystalline penicillin dissolved in physiological saline 
would appear to be the preparation of choice. 
14 
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Pulmonary Infections. Pneumonia due to the pneu-
mococcic hemolytic streptococcus or staphylococcus all 
respond to penicillin in a striking manner. Since pneu-
monia due to the pneumococcus is the commonest bac-
terial pneumonia in medical practice, one may well con-
sider its management. First of all, the fatality rate in 
pneumococcic pneumonia following penicillin is be-
tween 3 and 5 per cent. Most of the deaths have occurred 
in patients who are treated late in the course of their 
disease, i.e., after the third or fourth day and in patients 
over 60 years of age with complicating diseases. The 
pneumococcus is very sensitive to the action of penicillin; 
therefore penicillin in aqueous solution in 100,000 units 
every eight hours, or 200,000 or 300,000 units in aqueous 
solution every twelve hours, is usually adequate for opti-
mum results. Patients also respond well to 300,000 units 
of penicillin in oil and wax or 300,000 units procaine 
penicillin in oil. Successful results have also been ob-
tained through the use of penicillin by mouth, with an 
initial dose of 200,000 units followed by 100,000 units 
every two hours. 
Pneumonia caused by the hemolytic streptococcus 
and staphylococcus is not common, but penicillin has 
proved to be highly effective in treatment. Both infec-
tions are likely to lead to abscess of the lung, so that 
prompt treatment is necessary. Pneumonia due to the 
staphylococcus is more difficult to treat than strepto-
coccus pneumonia because the organisms are more re-
sistant; however, 200,000 or 300,000 units of penicillin 
daily is usually adequate. In our own experience in the 
15 
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past seven years, staphylococcic pneumonia is seen most 
often as a complication or secondary infection in patients 
with epidemic influenza. 
Bacterid Endocarditis. Acute bacterial endocarditis 
due to the pneumococcus, the staphylococcus, the hemo-
lytic streptococcus has responded favorably in 40 to 70 
per cent of cases. The recovery rate has been lowest in 
the pneumococcic cases and highest in the hemolytic 
streptococcic cases. Inasmuch as many of these cases 
occur as a part of a general septic state in which the endo-
carditis was only one feature of the illness, it is not sur-
prising that the recovery rate varied. The minimum daily 
dosage in these cases should be at least 500,000 units. The 
doses should be divided into equal parts and given every 
four or six hours throughout the day. 
Subacute Bacterial Endocarditis. Prior to the intro-
duction of penicillin, subacute bacterial endocarditis was 
a fatal disease in at least 95 per cent of cases. A few pa-
tients recovered spontaneously, a few recovered follow-
ing sulfonamide or arsenic therapy, a few recovered fol-
lowing the ligation of a patent ductus arteriosus when 
there was a superimposed infective endocarditis, but by 
and large most patients with this disease died within a 
period of six to eighteen months after the onset of the 
disease. 
With the use of penicillin the outlook for these pa-
tients changed. Now, at least 70 per cent of patients re-
cover and have an arrest of their disease. The largest num-
ber of patients will recover when 500,000 units a day are 
given for at least six to eight weeks. When less than a 
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half million units are given a day, few patients recover 
and the relapse rate is higher. Deaths are due to t h e 
primary infection, to heart failure, to pulmonary e m b o -
lism, or to all three. Many of the patients who recover 
remain well for one to three years or more and show n o 
signs of a progressive disease. Patients who show signs o f 
heart failure at the time treatment is started usua l ly 
fail to recover completely, and if they recover from t h e 
signs of infection, often die within six months to a y e a r 
with cardiac insufficiency. 
If relapse of infection occurs, it is usually seen w i t h i n 
two weeks or two months after treatment is discontinued. 
Clostridial Infections. The various strains of Clostridia 
are sensitive to the action of penicillin in vitro and i n 
clinical infections. In all cases of clostridial infection, 
penicillin is only an adjunct to surgical treatment, s i n c e 
the adequate surgical removal of all necrotic and devita l -
ized tissue is the most important therapeutic procedure 
in the management of these infections. Penicillin i n 
doses of 500,000 to 1,000,000 units a day should be u s e d 
early in the course of the disease, and since most i n -
fections are mixed, it is well to combine the t reatment 
with sulfonamides. 
Actinomycosis. The best results in the treatment of 
this infection have been with the combined use of p e n i -
cillin and sulfadiazine. When it is possible to r e m o v e 
infected tissues, one should do so. Altemeier has h a d . a 
broad experience in this field. When sinuses are s u p e r -
infected with staphylococci, these organisms disappear 
promptly, and the sinuses may heal completely, but re-
currences in such cases are not unusual. 
17 
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Anthrax. Anthrax responds well to penicillin, and this 
drug is the treatment of choice. For the localized form 
of disease 100,000 to 200,000 units daily for three to seven 
days are adequate. When bacteremia is present, the 
treatment must be more intense and must be continued 
for a longer period of time. 
Diphtheria. Antitoxin should be used in treating all 
patients with diphtheria. Penicillin will frequently cause 
the diphtheria bacilli to disappear from the throat at a 
more rapid rate than when antitoxin is used alone. Our 
practice has been to use it in all cases, since the carrier 
rate is thus reduced following acute diphtheria. Treat-
ment requires 200,000 units daily for seven to ten days. 
The treatment of chronic carriers is more difficult, and 
while organisms disappear after seven to fourteen days' 
treatment following 300,000 units daily, one occasionally 
encounters failures. 
In addition to the specific diseases mentioned, peni-
cillin has proved to be the best chemotherapeutic agent 
for the treatment of acute and chronic osteomyelitis, 
otitis media, and mastoiditis. Penicillin is the drug of 
choice for the treatment of all infections due to gram-
positive microorganisms such as the staphylococcus, 
pneumococcus, and hemolytic streptococcus. It is also 
the best agent for the treatment of syphilis and gonor-
rhea. 
Penicillin as a Piophyhctic Agent. Penicillin has been 
used to prevent invasive infections when the normal de-
fense mechanism of the body ruptured, as occurs follow-
ing dental extraction, surgical removal of a lobe of a 
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lung, or operation in an infected field. Likewise, it h a s 
been employed to prevent streptococcic sore throat i n 
rheumat ic subjects. 
Prophylactic penicillin has proved to be very effective 
in preventing infection following thoracotomy for e x -
ploratory surgical procedures or for esophagectomy, a l s o 
for t h e prevention of empyema following lobectomy o r 
pneumonectomy; although in the case of lobectomy t h e 
incidence of infection was moderately high when b r o n -
chopleural fistulae developed. As a prophylactic measure 
in preventing infection after operations on bones a n d 
joints, penicillin has produced highly favorable results. 
Infection has been prevented in 80 per cent of c o m -
p o u n d fractures, and when infection has recurred, t h e 
organisms present have been gram-negative bacteria o r 
occasional cases of staphylococcus infections. All infec-
tions h a v e remained localized, and no cases of generalized 
infection have been reported. 
T o reduce the incidence of infection in patients w h o 
require skin grafting or to facilitate successful grafting 
in t h e presence of infection or contamination, penicillin 
has b e e n found useful. 
I n an attempt to reduce the number of cases of b a c -
teremia following tooth extraction in patients with r h e u -
mat ic heart disease or previous attacks of subacute b a c -
terial endocarditis, penicillin has been used with success. 
Var ious dosage schedules have been employed, includ-
ing 50,000 units twenty minutes prior to tooth extraction 
as a single injection or 50,000 units intramuscularly e v e r y 
two hours for twelve doses prior to extraction. 
I. PENICILLIN 
In summary, then, one may say that within a few years 
penicillin has made an extraordinary change in the out-
look and prognosis of many infections. No other nontoxic 
agent has done so much for so many infectious diseases. 
It is a truly remarkable agent. 
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S t r e p t o m y c i n in tlie Treatment 
of In fect ions 
(Streptomycin was described i n 
1944 by Schatz, Bugie, and Waksman. The active sub-
stances are the product of the growth of Streptomyces 
griseus, one of the higher bacteria found in heavily-
manured soil, although the original strain was isolated 
from the throat of a chicken. Streptomycin is active 
against both gram-positive and gram-negative organisms 
as wel l as the tubercle bacillus. The toxicity of strepto-
mycin for man and animals is low, and this antibiotic i s 
active against a number of infections in man. 
Recent studies have demonstrated the fact that 
streptomycin as it was originally defined is not a single 
chemical entity but a mixture of at least two chemically 
related substances. The major constituent, sometimes 
known as Streptomycin A, is now known to be an o-gly-
coside of the disaccharide streptobiosamine with strep-
tidine. The second constituent, sometimes known a s 
Streptomycin B, is o-mannosido-N-methyl-L-glucosamin-
ido-streptosido-streptidine. 
I n addition to these two substances the organism 
produces at least two and possibly three or more anti-
biotics. One is produced by the mycelium and has re -
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mained unnamed. Another, des ignated as " a c t i d i o n e , " i s 
found in the culture filtrate and i s active only a g a i n s t 
fungi. 
Waksman has recently suggested the following n o -
menclature, which may be a d o p t e d : 
Streptomycin complex—a t e r m applied to a l l 
crude or partially purified preparations containing v a r i o u s 
forms of streptomycin and i n a c t i v e impurities in u n -
known proportions. 
Streptomycin—the c o m p o u n d formerly k n o w n a s 
Streptomycin A, or N-methyl-L-glncosaminido-strepto-
sido-streptidine. 
Mannosidostreptomycin—the compound k n o w n 
as Streptomycin B. 
Streptomycin residue—substances which r e m a i n 
after the removal of purified s t reptomycin from i m p u r e 
streptomycin, and which may have antibiotic propert ies 
or act as enhancement factors. 
Streptomycin-like substances—any preparations, 
produced by the organism, which show an ant ib iot ic 
spectrum and other biological and chemical properties 
similar to those of streptomycin. O n e such substance has 
been designated Streptomycin I I b y Johnstone a n d 
Waksman. 
Streptomycin complex is an o r g a n i c base w h i c h 
readily combines with acid radicles such as the hydro-
chloride and the sulfate or with c a l c i u m chloride to form 
the double salt calcium chloride s t reptomyc in complex . 
All of these salts are available, and w h i l e the complex is 
a mixture of streptomycin and mannosido-streptomycin, 
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both substances have an antibiotic spectrum. The latter 
differs quantitatively from the former. Only time and 
experiment will determine whether pure compounds are 
capable of producing more favorable chemical results 
than the complex and also whether one product is more 
toxic than the other. 
W h a t I shall say here applies to the use of strepto-
mycin complex in the treatment of infections in man. 
T h e streptomycin salts are readily soluble in water or 
glucose solution, so that one gram can be dissolved 
readily in one or two milliliters of fluid. Absorption from 
the muscles occurs promptly following injection, but 
practically none is absorbed from the gastrointestinal 
tract. 
M o s t of the streptomycin is excreted by the kidney 
into the urine and some is excreted in the bile. Very little 
diffuses into the cerebrospinal fluid, but it passes into the 
various tissues of the body so that it can be found in the 
pleural, peritoneal, and ocular fluids in concentrations 
lower than that of the blood. It passes through the pla-
centa and is found in the fetal circulation. 
BACTERIAL RESISTANCE AND SENSITIVITY 
It is now generally recognized that there is a great 
variation in the sensitivity of various organisms to the 
action of streptomycin. It is desirable to know about the 
sensitivity of the organism that is causing infection in 
order that enough streptomycin may be given for the 
concentration in the blood and tissues to inhibit the 
growth of the infecting organism. Table 1, taken from 
a paper by Murray, Paine, and Finland, lists the reported 
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range and the sensitivity most frequently encountered in 
a wide variety of microorganisms. This table clearly indi-
cates that there is a wide variation in the sensitivity of 
different organisms to streptomycin. It is striking that 
there is also considerable variation from one strain to 
another within the same species. 
Inasmuch as it has been demonstrated that in the 
presence of blood or serum the tolerance of microorgan-
isms to streptomycin may be increased four to eight 
times, it is desirable to maintain a concentration in the 
blood four to eight times that necessary to inhibit com-
pletely the growth of organisms in vitro. 
A notable feature of the use of streptomycin m the 
treatment of infections is the rapidity with which many 
bacteria acquire resistance to it. That is to say, after treat-
ment with the drug, organisms appear in local foci of 
infection that cannot be killed by concentrations ob-
tainable by the clinical use of the drug. The rapid devel-
opment of resistance should encourage one to adopt the 
maximum dosage that is indicated in the very beginning 
of treatment. While it has not been demonstrated that 
all resistant bacteria are virulent and cause continuing 
infection, the appearance of resistant organisms may 
account for a number of streptomycin failures. 
SIDE REACTIONS 
There are two important side reactions to strepto-
mycin: neurologic disturbances, characterized by tinni-
tus, vertigo, or deafness; and hypersensitive reactions, 
characterized by fever, skin eruptions, and eosinophilia. 
Pain in the muscles at the site of local injection is com-
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Range Frequent 
Actinomyces bovis 4 
Aerobacter aerogenes 0.5-128 6-25 
Bacillus anthracis 0.5 
Bacillus cereus 0.8-2 
Bacillus megatherium 0.25-8 
Bacillus subtilis 0.1-128 1-8 
Brucella abortus 0.5-4 
Brucella melitensis 0.5-2 
Brucella suis 0.5-3 
Clostridium perfringens (Welch bacillus) > i o 4 
Clostridium septicum (Vibrion septique) > i o 5 
Clostridium sordellii > i o 5 
Clostridium tetani > i o 4 
Coccidioides immitis >3oo 
Corynebacterium diphtheriae 0.4-4 
Diplococcus pneumoniae (pneumococcus) 4-50 
Diphtheroids 1 ->128 
Eberthella typhosa 1-120 1-16 
Erysipelothrix muriseptica 2.5 
Escherichia coli (various strains) 0.3-128 <8 
Haemophilus ducreyi (chancroid) 
Haemophilus hemolyticus 0.8-3 
Haemophilus influenzae (Pfeiffer's bacillus) 1-50 1-5 
Haemophilus parainfluenzae 
Haemophilus pertussis 1-15 
Histoplasma capsulatum >2500 
Klebsiella ozaenae 0.2-1.5 
Klebsiella pneumoniae 
(Friedlander's bacillus) 0.2-128 0.6-8 
Listerella monocytogenes 2.5 
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TABLE I 
SENSITIVITY OF VARIOUS ORGANISMS TO STREPTOMYCIN 
Organism Reported Sensitivity1 
Most 
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TABLE I (cont.) 
Organism Reported Sensitivity1 
Most 
Range Frequent 
Malleomyces mallei (glanders) 10->10 
Mycobacterium tuberculosis (avian) 10-50 
Mycobacterium tuberculosis 
(human and bovine) 0.1-1 
Neisseria catarrhalis 1-4 
Neisseria gonorrhoeae (gonococcus) 5-40 10-15 
Neisseria intracellularis (meningococcus) 1-40 
Nocardia 4-12.5 
Pasteurella pestis (plague) 0.5-1.5 
Pasteurella tularensis 0.1-0.3 
Paracolon bacillus 2-128 2-16 
Proteus morgani 1-128 8.-50 
Proteus vulgaris 0.4-128 4-25 
Pseudomonas aeruginosa 
(Bacillus pyocyaneus) 2-200 8-50 
Salmonella (various species) 4-120 4-32 
Sarcina lutea 0.25 
Serratia marcescens (Bacillus prodigiosus) 1-64 
Shigella (various species) 0.2-8 3-7 
Staphylococcus albus 1-256 1-4 
Staphylococcus aureus o-5->i28 1-8 
Streptococcus faecalis 12.5-60 
Streptococcus hemolyticus 1 ->128 2-32 
Streptococcus, nonhemolytic 1 ->128 1-32 
Streptococcus viridans 0.1->128 1-32 
Streptomyces (various species) 0.4-12.5 
Veillonella gazogenes 10 
Vibrio comma (cholera) 5->5oo 
1 Minimum inhibiting concentration of streptomycin in micrograms per cubic 
centimeter of culture. 
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plained of by a number of patients regardless of the prep-
aration used. It is more frequent when large amounts— 
0.5 to 1 gm.—are given at a single injection in relatively 
large volumes of fluid; that is, more than 2 cubic centi-
meters. It is desirable to change the site of injection fre-
quently and to use as small a volume of streptomycin as 
possible. One cubic centimeter of 1 per cent solution of 
procaine hydrochloride may be given with each injection 
to minimize pain. 
Histamine-like reactions were described when strep-
tomycin was first introduced. These are no longer en-
countered because the method of preparation has elimin-
ated histamine from the product. 
Sensitization reactions are characterized by fever and 
skin eruptions in about 5 per cent of patients. The erup-
tions may be erythematous, urticarial, maculopapular, 
or even hemorrhagic. The rashes appear most often be-
tween the third and tenth day of treatment, but they 
may be observed as early as the second day. Sometimes 
they do not occur until after treatment has been stopped. 
Their duration is extremely variable. They may be tran-
sitory and disappear within one to three days in spite of 
continuation of treatment, whereas in other cases they 
may last for seven to nine days after treatment is discon-
tinued. Skin eruptions may or may not be accompanied 
by fever. When fever is present it usually persists for one 
to five days. Rarely fever occurs without skin eruption. 
When patients have developed a skin eruption fol-
lowing streptomycin, they frequently react to a single in-
jection at a later date, with the reappearance of a rash or 
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fever. One should, t h e r e f o r e , ask every patient who is 
about to receive s t r e p t o m y c i n whether or not he has re-
ceived it previously. T h e l o n g e r the interval of time be-
tween the initial h y p e r s e n s i t i v e reaction and the reinjec-
tion, the less likely o n e is t o observe the recurrence of 
fever and a skin rash f o l l o w i n g a reinjection. 
In general it is a d v i s a b l e t o stop streptomycin if the 
skin eruption appears. C e r t a i n l y the dosage should be 
reduced, and if t r e a t m e n t is continued it should be car-
ried forward with c o n s i d e r a b l e caution. Relief from the 
burning and itching t h a t m a y b e associated with the skin 
eruption may be o b t a i n e d b y t h e use of benadryl in 50-
to roo-mg. doses three or f o u r times a day. 
Eosinophilic E o s i n o p h i l i a as a sign of hypersensi-
tivity to streptomycin w a s first reported by McDermott. 
The eosinophils may b e 5 p e r cent or higher, and the 
eosinophilia may c o n t i n u e throughout treatment. It may 
be an accompanying f e a t u r e o f the skin eruption, but it 
may also appear w i t h o u t a n y eruption whatsoever. So 
far there has been n o c o r r e l a t i o n between the eosino-
philia and the onset of n e u r o l o g i c symptoms, although 
the two are occasionally p r e s e n t in the same patient. 
Neurologic Disturbances. T h e three neurologic ab-
normalities that have b e e n described are disturbances in 
equilibrium (vertigo w i t h o u t the rotary component), 
deafness, and tinnitus. Occas iona l l y patients have com-
plained of paresthesias i n t h e region of the second and 
third branch of the fifth c r a n i a l nerve. Also, there has 
occasionally been some t rans i tory blurring of vision in 
patients. These c o m p l a i n t s a r e usually temporary and 
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disappear within several days after the drug has been 
discontinued. 
Vertigo. In virtually all patients receiving as much as 
3 gm. of streptomycin a day, vertigo has been observed 
between the seventeenth and twenty-fifth days. It is 
much less frequent when smaller doses are used; that is, 
0.5 to 1 gr. a day for five to fourteen days. When the dis-
turbance in equilibrium occurs early, it is most often com-
plained of during the first five days. It may be severe or 
mild, and it may last from one day in the very mild cases 
to thirty or sixty days in the severe ones; in some cases 
ft has persisted for as long as six to nine months. In the 
patients described by McDermott, all were completely 
free of symptoms at the end of four months. In one out 
of ten patients with disturbances of equilibrium, the 
symptom is severe. It may be associated with nausea and 
vomiting. In half the patients it is moderately severe, 
and in about a third it is negligible. Disturbance in equi-
librium is most noticeable after sudden movement such 
as turning over or sitting up in bed, but at the height of 
the reaction patients are uncomfortable even when lying 
flat. The acute symptoms persist for seven to ten days 
and then gradually subside to such a degree that only an 
unusual stimulus like sudden shaking of the head pro-
duces transitory symptoms. Rarely, patients continue to 
feel unsteady at the beginning of walking or after rising 
from a chair, and this condition may persist for a number 
of months. 
Deafness. This reaction has been reported under sev-
eral different circumstances: first, when very large daily 
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doses of streptomycin—6 to 9 gm.—are used; secondly, 
in patients with marked renal insufficiency; and thirdly, 
in patients who have meningitis and receive the drug 
intrathecally. The deafness varies tremendously, both in 
degree and in duration. In some cases it is transitory and 
is often associated with tinnitus. This is particularly true 
of patients who have become deaf after receiving rela-
tively small amounts of streptomycin within the first 
week of treatment. In others the deafness is permanent, 
and it may be complete or the hearing may be reduced by 
approximately 50 per cent. 
Tinnitus. This is a frequent complaint and may be 
associated either with deafness or with disturbances in 
equilibrium. It has occurred in approximately 5 per cent 
of the cases reported to the Committee on Chemother-
apy. It usually disappears following the discontinuance of 
streptomycin. 
ROUTES OF ADMINISTRATION 
There are three common routes of administration of 
streptomycin: intramuscular, subcutaneous, and topical, 
including intrathecal, intraperitoneal, and intrapleural. 
Solutions may be dropped into the conjunctival sacs, into 
the nasal passages, or into the external auditory canal. 
The drug has been given by means of gauze soaks on cu-
taneous areas and by inhalation, and it has also been in-
troduced into the urinary bladder and kidney pelves. 
The oral route is employed when a local effect in the 
intestinal tract is desired, but this route is of no value in 
the treatment of systematic infections, for the reason 
that so little streptomycin is absorbed from the gastroin-
testinal tract. 
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For all systemic infections, the intramuscular route 
is the one of choice. Streptomycin may be given subcu-
taneously, but it is more likely to cause pain and local 
irritation by this route than by the intramuscular one. In 
the treatment of meningitis, both intramuscular and in-
trathecal injections are necessary for optimum results. In 
empyema, intrapleural injections are desirable; in peri-
tonitis, intramuscular and in some cases intraperitoneal 
injections are required. There is no advantage in giving 
streptomycin intravenously, since it is readily absorbed 
from the muscles. 
Intramuscular Injections. When the intramuscular 
method is used, the maximum serum or plasma concen-
trations of streptomycin are obtained within one to three 
hours after single injections, and there is a gradual de-
crease in the concentration over a period of ten to 
twelve hours. There is a correlation between the plasma 
concentration and the amount of streptomycin adminis-
tered. Additive effects are obtained by repeating the in-
jections at four-hour intervals. 
In general, it can be said that the total daily dose may 
be divided into two or four equal amounts and given 
every six to twelve hours throughout the day. 
Following intramuscular injection, streptomycin 
enters the blood and passes freely into the pleural fluid, 
the peritoneum, the ocular fluid, and the bile. It diffuses 
across the placenta into the fetal circulation and amniotic 
fluid, and it has been found in the umbilical cord blood 
and amniotic fluid within ten minutes after intravenous 
injection into the maternal circulation. Very little strep-
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tomycin diffuses into the cerebrospinal fluid. There is 
also evidence that it diffuses into the pus of soft-tissue 
abscesses, and it can be found in the kidney and other 
tissues of the body in varying concentration following 
intramuscular injection. While the drug diffuses into the 
pleural and peritoneal fluid, the concentration is usually 
lower than that of the blood. The same is true for bile, 
ocular fluid, and the fetal blood and amniotic fluid. 
In brief, then, streptomycin diffuses from the blood 
into the body fluids and tissues, but the concentration in 
the various tissues is usually much lower than that in the 
circulating blood. 
There is no good evidence that streptomycin is de-
stroyed in the body. Most of it is excreted by the kidneys 
into the urine; small amounts are excreted into the bile 
and appear in the feces. At least 60 to 80 per cent of the 
streptomycin that is injected intramuscularly may be re-
covered in the urine within a 24-hour period. 
Subcutaneous Injection. It has already been stated 
that intermittent subcutaneous injection may be used 
in place of intramuscular injection. It is much more 
likely, however, to cause pain and local irritation, and 
this route has no advantage over the intramuscular one. 
Maximum plasma concentrations are observed within 
two to three hours after subcutaneous injection. 
Intrathecal Injection. Following intrathecal injection 
streptomycin leaves the subarachnoid space slowly, so 
that relatively high concentrations can be detected in the 
cerebrospinal fluid throughout a 24-hour period follow-
ing a single injection of as little as 20 mg. The average 
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amount injected intrathecally should be 25 to 50 mg. 
daily; in some cases it may be necessary to use as much 
as 100 mg., but this amount should not be exceeded and 
should be used only when an unfavorable response has 
been obtained with smaller dosage in patients with bac-
terial meningitis. 
Oral Administration. So little streptomycin is ab-
sorbed from the gastrointestinal tract that it should not 
be given by this route unless one is anxious to reduce the 
total number of bacteria in the stools. This method of 
therapy has been used as a prophylactic measure in pre-
paring patients for surgical operations on the large bowel. 
It has also been employed without much success in the 
treatment of local and systemic infections beginning in 
the intestine, such as typhoid fever and Salmonella in-
fections. Two to 3 gm. a day by mouth may be necessary 
to reduce the number of bacteria in the stools. 
Inhalation. Streptomycin can be inhaled in aerosol-
ized solutions for the treatment of bronchopulmonary 
infections due to gram-negative bacilli, or it may be com-
bined with penicillin when a mixed infection is present. 
Concentrations of 50 mg. per cubic centimeter may be 
inhaled after the drug has been nebulized, so that a total 
amount of 500 mg. in a 24-hour period is administered 
in this way. Only small amounts of streptomycin are ab-
sorbed from the lungs, so that very little is detected in the 
blood plasma and small amounts may be recovered from 
the urine. 
RESPONSE IN VARIOUS DISEASES 
Tularemia, All clinical forms of tularemia respond to 
streptomycin in a remarkable manner. In fact, it can be 
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said that streptomycin is the most important c h e m o t h e r -
apeutic agent available today for the treatment o f this 
disease. The results from it have been striking. T h i s is 
one of the infections in which relatively small a m o u n t s 
of streptomycin have been used successfully. F i v e - t e n t h s 
to l g m . a day in divided doses every six hours for s i x days 
is usually adequate to control either the ulceroglandular 
or the pneumonic form of tularemia. Intermittent i n t r a -
muscular injections given over a period of six d a y s are 
usually followed by a period of rapid decrease i n the 
temperature within forty-eight to seventy-two h o u r s a n d 
by improvement in the constitutional symptoms. T h e r e 
is a more gradual decrease in the size of the lymph n o d e s , 
often without suppuration, and a slow regression o f the 
X-ray and physical signs of pneumonitis when t h e y are 
present. The clinical results of treatment have b e e n ex-
tremely impressive in the typhoidal form of the d i s e a s e , 
as well as in the ulceroglandular and pulmonary f o r m s . 
A l l patients suspected of having tularemia s h o u l d be 
treated promptly, for the reason that the results a r e so 
striking and impressive. 
Brucellosis. Experimental studies of brucellosis in 
guinea pigs showed quite clearly that when the i n f e c t i o n 
is treated early—that is, within one week after i n o c u l a -
tion—and when adequate amounts of streptomycin are 
given daily for a period of at least three weeks, the i n f e c -
tion may be controlled and organisms eliminated f r o m 
the body. Many strains of Brucella are highly suscept ib le 
to streptomycin in vitro. The results of the t r e a t m e n t of 
human infections, however, have on the whole b e e n very 
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disappointing, for the reason that these organisms seem 
to be extremely resistant in the body. It is generally 
agreed by those who have studied cases of acute brucel-
losis that no dramatic effects are observed in any case 
with the treatment schedules that have been employed. 
During treatment with streptomycin the blood is 
often cleared of organisms if there is a bacteremia, and 
the temperature has returned to normal in one-third of 
the cases. There is very little evidence that the febrile 
phase of the disease has been shortened, except in those 
cases in which the disease has been treated within the 
first two or three weeks after the onset of symptoms. 
The fatality rate has not been decreased so far, al-
though the total number of cases reported is small. T h e 
febrile relapse rate is approximately 9 to 10 per cent i n 
patients who have been treated. The blood has been 
cleared of organisms in 80 per cent during treatment, a l -
though in 10 per cent of patients there has been a re-
lapse of the bacteremia as soon as treatment has been 
stopped, and in approximately another 10 per cent the 
organisms are never cleared from the blood by ten days 
to two weeks of treatment. A dosage of 2 gm. a day for 
periods of two weeks is suggested during the acute febrile 
phase of this disease when symptoms have been present 
for less than four weeks. There is no evidence that strep-
tomycin has had any effect on the chronic cases of bru-
cellosis, although during an acute exacerbation with bac-
teremia one may be able to clear the blood and to bring 
about a decrease in the temperature. Recent studies have 
shown that when sulfadiazine is combined with strepto-
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mycin and continued for four weeks, excellent results 
have been obtained in the acute cases. 
Typhoid fever. Streptomycin has produced no dra-
matic effects in typhoid fever. It has not decreased the 
fatality rate nor the relapse rate. There is some suggestive 
evidence that in patients treated during the first ten to 
fourteen days of their illness the febrile period of the 
disease is shortened. There is no evidence that treating 
patients after the fourteenth day of illness influences the 
disease in any way. 
Salmonella Infections. The results in the treatment 
of Salmonella infections, both those that produce acute 
gastroenteritis and those that cause enteric fever, have 
been disappointing. Occasionally one sees a temporary 
disappearance of organisms from the stools following the 
oral and systemic administration of streptomycin, but 
the total duration of the disease does not seem to be 
shortened. It is not clear why the results have been so 
unsatisfactory in patients who have an infection due to 
organisms that are susceptible to streptomycin in vitro. 
Endocarditis. Most cases of bacterial endocarditis 
are due to gram-positive microorganisms that are sensi-
tive to the action of penicillin. A few cases are due to 
gram-negative bacilli or to organisms that are penicillin-
resistant and streptomycin-sensitive. Such cases have 
been studied especially by Hunter at the Presbyterian 
Hospital in New York City. On the basis of the exper-
ience reported by him, streptomycin should be given a 
trial in all infections due to gram-negative bacilli or to 
penicillin-resistant gram-positive cocci, and in infections 
that have failed to respond to penicillin therapy. 
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The dosage recommended by Hunter is 2 to 6 gm. a 
day for a period of two to four weeks, depending on the 
sensitivity of the organism and the clinical response. In 
some cases of endocarditis caused by microorganisms that 
show in vitro sensitivity to both penicillin and strepto-
mycin, a course of therapy with both drugs together has 
been used with success. It should be emphasized that 
when large doses of streptomycin are given, such as 4 to 
6 gm. a day for two to four weeks, neurologic symptoms 
are likely to occur. Some patients may even develop deaf-
ness, and for this reason audiometer and vestibular func-
tion tests should be made at regular intervals during 
treatment. 
Peritonitis. Experimentally streptomycin reduces the 
fatality rate in animals with peritonitis, and it has been 
recommended along with penicillin and the sulfona-
mides in the treatment of all cases of established periton-
itis in man. There now exists suggestive evidence that 
streptomycin has had a beneficial effect in a number of 
cases of peritonitis due to gram-negative bacilli. In some 
instances the organisms are mixed, and in others single 
strains are responsible for the peritonitis. It is recom-
mended, therefore, that streptomycin be used along with 
other chemotherapeutic agents, and other established 
forms of treatment, in all cases of peritonitis. 
Wound Infections. The treatment of established in-
fections of wounds is a complicated procedure. The use 
of penicillin and the sulfonamides will prevent invasive 
infections due to susceptible organisms in wounds. These 
drugs aid in the sterilization of local foci of infection. 
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Sooner or later gram-negative bacilli appear in all chronic-
infected wounds, and they may dominate the bacterio-
logic flora. There are those who hold that gram-negative 
bacilli do not interfere with the healing of wounds, but 
the studies of Howes stress the fact that they definitely 
do so. Howes has also presented good experimental evi-
dence that streptomycin can be given topically to rid 
wounds of persistent gram-negative bacilli when no 
slough is present. 
On the basis of these observations it can be said that 
a solution of streptomycin in a concentration of 200 mg. 
per cubic centimeter can be used in freshly wounded tis-
sues without further damage, and that wounds so treated 
heal without delay. Furthermore, it has been shown that 
granulations are not damaged by a thousand units of 
streptomycin per cubic centimeter. Streptomycin, then, 
can be said to be the best nontoxic antibiotic that has 
been discovered so far for destroying gram-negative 
bacilli. 
It has been recommended that penicillin in concen-
trations of a thousand units per cubic centimeter or 5 
per cent sulfamylon should be combined with strepto-
mycin when it is used topically. The purpose of this com-
bined chemotherapy is to assist in the killing of suscepti-
ble bacteria of both the gram-positive and gram-negative 
groups. As adjuvants to therapy, when slough is present, 
Howes has demonstrated that resolution of the estab-
lished localized infection can be hastened by the use of 
chemicals that will liquefy slough and permit antibac-
terial substances to penetrate and kill the bacteria that 
remain. 
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Shigella Infections. A few patients with sulfonamide-
resistant bacillary dysentery have been treated with strep-
tomycin given by mouth in doses of 5 gm. a day for four 
days. Diarrhea and fever subsided in twelve hours and 
the causative organisms disappeared from the stools. 
There is suggestive evidence, therefore, that certain cases 
of bacillary dysentery that are resistant to the sulfona-
mides may respond in a striking manner to streptomycin 
by mouth. 
Cholera. Streptomycin has been used in the treat-
ment of a few patients with cholera. It was given by 
mouth in doses of 4 gm. a day, with an occasional intra-
venous injection. There is no clear indication that it had 
any advantage over large amounts of fluid and the sul-
fonamides. It is true, however, that the number of chol-
era Vibrio diminished in the stools following treatment, 
although some were still present there and had increased 
in resistance. 
Infections of the Eye. Corneal ulcers due to Pseudo-
monas aeruginosa and Escherichia coli have been treated 
successfully by a streptomycin solution instilled into the 
conjunctival sac. Ps. aeruginosa ulcers of the cornea are 
always serious and difficult to cope with, so that strepto-
mycin should be used in all such cases. 
Infections of the Ear. Infections of the middle ear 
due to gram-negative bacilli have responded with great 
irregularity to streptomycin. Usually surgical treatment 
is needed along with chemotherapy if satisfactory results 
are to be obtained. 
Urinary-tract Infections. Acute and chronic urinary-
tract infections due to susceptible microorganisms, usu-
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al ly of the gram-negative group, have responded i n a re-
markable way in at least 40 to 60 per cent of t h e cases 
following the use of streptomycin. Following parenteral 
injection 60 to 80 per cent of the amount in jected is re-
covered in the urine within twenty-four to forty-eight 
hours. Streptomycin usually appears in high concentra-
t ion, depending on the renal function, the v o l u m e of the 
urine, and the dose administered. It is much m o r e active 
when the urine is alkaline, so that it is desirable to use 
alkalis along with streptomycin to render the u r i n e al-
kaline if it is not already so. In susceptible cases t h e urine 
i s usually sterilized within a period of seventy-two hours. 
Failure to sterilize the urine within this period o f t i m e is 
generally due to resistance of the infecting organism, the 
presence of an obstruction in the urinary tract, a n undis-
covered abscess, or a foreign body. It is practically im-
possible to sterilize the urine when there is a n inlying 
catheter or when stones are present. 
The commonest microorganism causing urinary-tract 
infections are Escherichia coli, Aerobacter aerogenes , 
Proteus vulgaris, Pseudomonas aeruginosa, and Strepto-
coccus faecalis. At least 75 per cent of the strains of Esch. 
co l i , P. vulgaris, and A. aerogenes are sensitive t o a con-
centration of 20 mg. per cubic centimeter of s t reptomy-
c i n . Strains of Strept. faecalis and Ps. aeruginosa a r e often 
extremely resistant in the very beginning and require con-
centrations of at least 100 mg. or more to inh ib i t their 
growth. When streptomycin is given to patients with 
acute or chronic pyelonephritis, constitutional s y m p t o m s 
a n d signs of infection frequently disappear p r o m p t l y . 
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Clinical improvement occurs in 50 to 60 per cent of the 
patients within a 72-hour period. Symptoms referable to 
the urinary tract respond more irregularly. 
It has been our experience that when the urinary out-
put is restricted to 2000 cubic centimeters a day and the 
daily dose of streptomycin is 1 gm., the concentration of 
streptomycin in the urine averages about 100 mg. per 
cubic centimeter. This is usually adequate for the treat-
ment of most urinary-tract infections, provided other 
factors are favorable for sterilizing the urine. When re-
sistant organisms such as Ps. aeruginosa and Strept. fae-
calis are present, a higher urinary concentration of strep-
tomycin is desirable, and a daily dose of 2 gm. should be 
given. When single organisms are present, sterilization of 
the urine occurs in about 40 per cent of the cases. Bac-
teriuria is diminished, at least temporarily, in practically 
all patients. Infections due to a single organism generally 
respond much more favorably than those in which a 
mixed bacterial flow is present. Any patient who fails to 
respond within twenty-four to seventy-two hours should 
be suspected of having a resistant organism or some un-
derlying anatomical lesion interfering with the free flow 
of urine, a foreign body, or an undrained abscess. It 
should be remembered that bacteria exposed to strepto-
mycin may, if the strains have become resistant to it, 
often respond to other chemotherapeutic agents. 
In summary, then, in the treatment of urinary-tract 
infections it is desirable to study the organisms that are 
causing infection in order to determine their resistance, 
and also to examine the patient for an explanation of the 
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underlying cause of infection. When obstructions are 
present, plans should be made to establish a free flow of 
urine or for the removal of stones. The urinary output 
should not exceed 2000 cubic centimeters a day. Strepto-
mycin should be given intramuscularly in 1-gm. doses for 
a period of five to seven days, and the urine should be 
kept alkaline during this time. It is usually unnecessary 
to continue treatment longer than seven to ten days un-
less bacteremia and an invasive infection are present. 
Under these circumstances it may be necessary to con-
tinue treatment for as long as two to three weeks before 
the infection is under complete control. 
Hemophilus Influenzae Meningitis. There is now a 
considerable body of evidence indicating that when 
streptomycin is used alone for the treatment of Hemo-
philus influenzae meningitis, and is given both intramus-
cularly and intrathecally, the recovery rate is high. When 
the treatment is started late in the course of the disease, 
the results may be irregular. Streptomycin, then, should 
be given in all cases of H. influenzae meningitis. It may 
be used alone when the disease is treated early, but if 
treatment is not started until late in the course of the ill-
ness, sulfadiazine and antiserum should perhaps be 
added. 
The intramuscular dosage usually employed is 25 mg. 
per pound of body weight daily and 20 to 50 mg. per day 
intrathecally. On this regimen the organisms generally 
disappear from the blood and cerebrospinal fluid within 
forty-eight to seventy-two hours and the constitutional 
symptoms decrease. Treatment should be continued for 
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at least seven to ten days or longer, depending on t h e 
clinical and bacteriologic response. 
Meningitis Due to Miscellaneous Gram-Negative Ba-
cilli. Occasional cases of meningitis are caused by Escher-
ichia coli, Pseudomonas aeruginosa, Klebsiella pneumo-
niae, Proteus vulgaris, Alcaligenes faecalis, Proteus mor-
ganii, Salmonella choleraesuis, and Aerobacter aerogenes. 
The fatality rate in these cases tends to be high, although 
the use of streptomycin both intramuscularly and intra-
thecally in adequate doses early in the course of t h e 
disease has been followed by favorable results. Infections 
of the central nervous system by these organisms respond 
poorly to the sulfonamides and are not helped by penicil-
lin. When patients are treated early it is clear that strep-
tomycin has been responsible for recoveries, and it should 
be given in all cases. One gram a day intramuscularly i n 
divided doses and 25 to 50 mg. a day intrathecally, with 
treatment continued for six to ten days depending on t h e 
clinical response, is the regimen to be followed. 
Bacteremia. Bacteremias due to a wide variety of 
gram-negative bacilli, with or without localizing signs of 
infection, can be cleared by streptomycin in many cases 
and the local infection responsible for the blood invasion 
can be controlled. Infections with bacteremia due to a 
variety of organisms have been treated. These include 
Escherichia coli, Proteus vulgaris, Pseudomonas aerugi-
nosa, Aerobacter aerogenes, Klebsiella pneumoniae, H e -
mophilus influenzae, and Salmonella. In all these cases 
the fatality rate has been reduced, and in patients w h o 
have recovered the streptomycin was important in con-
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trolling the local infection. It is generally agreed that the 
prognosis in such cases is determined in some measure 
by the nature and severity of the local lesions from which 
the invasion of the blood stream occurs. In some cases, 
also, it is known that the bacteremia is a transitory one 
and often follows trauma in an infected area. The age of 
the patient, the site and extent of the initial lesion, the 
species of infecting organism, the presence of complicat-
ing and debilitating diseases, and the duration of infec-
tion must be taken into account in assessing the results 
of treatment. All patients with bacteremia should receive 
l to 3 gm. of streptomycin daily for a period of seven to 
ten days. 
Pulmonary Infections. The two commonest organ-
isms causing acute infection of the lungs that are suscep-
tible to streptomycin are Hemophilus influenzae and 
Klebsiella pneumoniae. These infections may be either 
acute or chronic and either primary or secondary. In the 
chronic infections there is always some underlying ana-
tomical lesion, such as bronchiectasis, that contributes to 
the infection. In the acute infections with pneumonitis 
due to Kleb. pneumoniae and H. influenzae, the results 
of streptomycin treatment have been impressive. In the 
chronic infections, on the other hand, they have been 
transitory. H. influenzae infection of the lungs is seen 
most often in infants and young children. Here a diffuse 
capillary bronchitis or bronchopneumonia is frequent, 
and in about half the patients it is accompanied by bac-
teremia. Streptomycin has been highly successful in the 
treatment of these acute infections in infancy and child-
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hood. In Kleb. pneumoniae infections the acute infection 
is often controlled so that the process does not go on to 
abscess formation and pulmonary fibrosis. In view of the 
serious character of pneumonia caused by Kleb. pneu-
moniae, its associated high fatality rate, and its tendency 
to produce multiple pulmonary cavities, prompt institu-
tion of large doses of streptomycin, preferably 1 gm. every 
four to six hours in adults, is indicated. 
It is a common experience to observe a change in the 
bacteriologic flora of the sputum of patients with pul-
monary infections who have been treated with antibiotic 
agents. Following penicillin it is not infrequent for the 
gram-positive organisms to disappear, or at least to be-
come less numerous, and for gram-negative organisms to 
appear in large numbers. In many cases it is extremely 
difficult to decide what role is being played by these or-
ganisms in continuing infections. In some cases they 
seem to be important, for the reason that following strep-
tomycin treatment the constitutional symptoms and 
signs of infection may disappear as the organisms dis-
appear from the sputum. In some of the mixed infections 
it may be necessary to give both penicillin and strepto-
mycin. 
Chronic Pulmonary Infections. Chronic bronchiecta-
sis, lung abscess, and empyema caused by gram-negative 
organisms may be helped by streptomycin, given either 
by the aerosol method or systemically. In many cases 
these infections are a mixed variety, so that it is necessary 
to use both penicillin and streptomycin. Penicillin elim-
inates only the penicillin-sensitive organisms, and in 
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some patients the infection persists owing to the presence 
of gram-negative bacilli which are penicillin-insensitive. 
In such cases the response to streptomycin has been en-
couraging. The number of organisms is decreased follow-
ing inhalations of streptomycin and the volume of the 
sputum may diminish. At least 0.5 gm. of streptomycin 
in 20 cubic centimeters of normal physiological salt solu-
tion should be given daily. One should emphasize that 
streptomycin is only palliative in these cases, but it offers 
great relief of symptoms, and in some cases arrests the 
progress of the disease. 
Tuberculosis. Soon after it had been demonstrated 
that streptomycin inhibits the growth of the tubercle 
bacillus in vitro, experimental studies were carried out in 
guinea pigs with tuberculous infection by Feldman and 
Hinshaw at the Mayo Clinic. They demonstrated quite 
conclusively that in at least 70 per cent of animals in-
fected with tubercle bacilli streptomycin was responsible 
for eliminating the organisms from the body. 
The most extensive studies on the effect of the drug 
in tuberculosis have been carried out by the Veterans 
Administration under the direction of Barnwell and 
Walker. Other important studies have been carried out 
by the Army and the Navy, by Hinshaw and Feldman 
and their associates at the Mayo Clinic, by McDermott 
and his associates at the New York Hospitals. 
It is proper to say at once that streptomycin is the 
only effective chemotherapeutic agent that can be used 
in man for the treatment of tuberculosis. In a few cases 
it has been combined with promine. In some cases ex-
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traordinary results have been observed. Let us review 
some of them. 
Acute Miliary Tuberculosis with or without Menin-
gitis. Patients with miliary tuberculosis without menin-
gitis have recovered from their acute disseminated proc-
ess in about two-thirds of the cases. These results have 
been obtained when patients have received 2.0 gm. of 
streptomycin daily for 120 days. The follow-up period has 
averaged four months to a year. When death occurs in 
this group it commonly occurs within six weeks of the 
initiation of treatment. In most of the fatal cases there 
has been no post-mortem evidence of healing of the le-
sion. In a few, however, evidence of healing is plain and 
consists of small fibrotic "hard" tubercles; many of them 
have lost their characteristic histologic appearance. Pa-
tients who relapse while under treatment often show an 
infection due to a resistant organism. In about half of the 
patients with miliary tuberculosis who recover from signs 
of disseminated lesions, meningitis appears within four 
weeks and four months after treatment has been started. 
In patients with both miliary tuberculosis and men-
ingitis only about 10 per cent have recovered following 
treatment. 
In patients with meningitis without miliary tubercu-
losis about one-third of the patients recover from the 
signs of acute infection, but only about 25 per cent are 
relieved of all evidence of central nervous system tuber-
culosis. Even in these cases the protein content of the 
cerebrospinal fluid continues to be elevated in spite of 
the normal cell count. 
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It has been suggested by the Veterans Administration 
group that the dosage schedule for miliary tuberculosis 
should be 2.0 gm. daily in five doses and that the treat-
ment should be continued from 90 to 180 days depend-
ing upon the response of the patient. When meningitis 
is present, the parenteral treatment should be combined 
with intrathecal injections of 0.05 gm. per day for the 
first week, then two or three times a week or less often as 
improvement takes place. In view of the favorable re-
sponses in children with miliary tuberculosis following 
the use of promine, it has been suggested further that 4.0 
gm. a day be given intravenously for two weeks followed 
by a week of rest. When promine is used the blood must 
be watched carefully, since a hemolytic anemia may oc-
cur. 
T h e results of treatment of these serious cases of tu-
berculosis may be summed up as follows: 
( 1 ) Patients with acute miliary tuberculosis re-
cover from the signs of infection more often when 
there are no signs of tuberculous meningitis present 
at the onset of treatment. 
(2) The optimum results have been obtained 
with 2 gm. of streptomycin intramuscularly for 120 
days in divided doses five times a day. 
(3) Fifty milligrams of streptomycin should be 
given intrathecally during the first week, then two or 
three times a week as improvement occurs. 
Failures are due most often to the following: 
( 1 ) The presence of meningitis. 
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Progressive Pulmonary Tuberculosis. The effect of 
streptomycin in some patients with progressive pulmo-
nary tuberculosis has been striking indeed. It is most im-
pressive in the patients with acute exudative lesions and 
in the areas of the lung where necrosis is minimal. The 
optimum time-dose schedules have not been completely 
worked out but the immediate results as judged by X-ray 
examinations would appear to be similar whether 1.8 or 
2.0 gm. are given daily in five divided doses for sixty or 
120 days, or whether 1.0 gm. is given for sixty days, either 
in five divided doses or in two equal doses. Between 75 
and 85 per cent of patients will show improvement on 
these dosage schedules. Soon after treatment is started 
there is often an improvement in the constitutional 
symptoms and signs. Fever is reduced, the appetite im-
proves, and the patients gain weight. Within one or two 
months of treatment, exudates are being absorbed and 
there is a gradual regression of the lesions. Extensions of 
the lesions while patients are under treatment are infre-
quent unless the tubercle bacilli become resistant to 
streptomycin. Between 15 and 20 per cent of patients 
have relapses of their infections after treatment is discon-
tinued. Only about 50 per cent of patients revert from a 
positive to negative sputum while under treatment, and 
with the continuation of treatment more than four to six 
weeks, the number of cases in which the tubercle bacillus 
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(2) The development of meningitis during or 
following the discontinuance of treatment. 
(3) The development of bacterial resistance. 
II. STREPTOMYCIN 
52 
becomes resistant to increasing amounts of streptomycin 
increases greatly. For example, it has been shown that 
only about 5 per cent of strains are resistant to 10 micro-
grams of streptomycin per cubic centimeter after four 
weeks of treatment, whereas 76 per cent of organisms are 
resistant after 120 days. In general, it can be said that one 
of the limiting factors in treating patients with tubercu-
losis is the development of resistant strains of tubercle 
bacilli. These organisms are virulent for guinea pigs. 
Progress of the tuberculous process has been noted in 
many resistant cases receiving streptomycin. In some 
cases, improvement was noted or continued even though 
resistant organisms were obtained on culture. In brief, 
however, streptomycin exerts little if any beneficial effect 
in cases with resistant organisms, and any improvement 
noted under these circumstances must be attributed to 
the natural defense mechanism of the disease. 
Draining Sinuses. Patients with draining sinuses from 
bone or lymph node tuberculosis improve in a striking 
manner following streptomycin. Sixty per cent of the 
sinuses heal, and about 25 per cent improve. The dose of 
1.0 gm. a day in two equally divided doses of 0.5 gm. each 
for 120 days is the advantageous dose. 
Tuberculosis of the Upper and Middle Respiratory 
Tract Striking results have been obtained in the treat-
ment of tuberculosis of the upper and middle respiratory 
tract, including the larynx, hypopharynx, trachea, and 
larger bronchi. Ulcerations have healed in a remarkable 
manner within three to six months of treatment, and one 
can observe these healing lesions by direct visual examin-
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ation. The positive effects follow both systemic and local 
treatment by the aerosol method. Systemic treatment ap-
pears to be the more effective of the two. The recom-
mended dosage is 1 to 2 gm. a day intramuscularly and 
0.5 gm. in divided doses by inhalation every two hours in 
concentrations of 50 mg, per cubic centimeter. 
Tuberculosis of the Urinary Tract Symptomatic im-
provement has been observed in some patients with tu-
berculosis of the urinary tract. The total number of tu-
bercle bacilli decreases, and in a few cases they disappear, 
at least temporarily. Pyuria diminishes, and there is an 
increase in the capacity of the bladder and a decrease in 
the frequency of urination. So far, the results of treat-
ment have not been of a permanent character, but appear 
to be palliative. One to 1.5 gm. a day is usually given for 
a period of two months or longer. 
Tuberculosis of Pleura, Peritoneum, and Intestine. 
Too few cases have been studied to make any statements 
concerning the final results, but outstanding improve-
ment has occurred in some of the cases reported after 
treatment for sixty to ninety days. 
In summing up, then, it can be said that streptomycin 
has a powerful effect on the tubercle bacillus, and that 
this effect is reflected in the results observed in certain 
forms of clinical tuberculosis. This drug should be re-
served for patients with a poor prognosis and for those 
who have an advancing lesion in spite of the usual medi-
cal treatment. It is desirable to use small doses, 1.0 to 1.5 
gm. daily for the shortest possible period of time that is 
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consistent with maximum improvement. In this way the 
number of reactions are reduced and the number of 
strains of tubercle bacilli that become resistant is like-
wise reduced. Studies now in progress in various institu-
tions in the United States should give additional infor-
mation that will guide the medical profession in the fu-
ture use of streptomycin. 
Prophylactic Use before Operations on the Large In-
testine. Zintel and his associates at the University Hospi-
tal in Philadelphia have shown that the oral administra-
tion of streptomycin reduces the total population of bac-
teria in the feces. They have used the drug, therefore, in 
doses of l to 2 gm. a day preoperatively, and streptomycin 
and penicillin postoperatively, in all patients operated on 
for resection of the large intestine. A greater number of 
such resections can be done with primary suture, and the 
chances of peritoneal infection are reduced, if streptomy-
cin is employed in this way. 
III. 
III. 
Antibacterial Agents f rom 
Microbes 
In selecting the topic of antibac-
terial agents from microbes, I want to sketch for you the 
origin of some of our most potent anti-infectious agents 
thus derived. I propose introducing the subject by telling 
you something about the history of the discovery and the 
cause of anthrax. This disease is now rare but historically 
important. Anthrax is a disease of both animals and man. 
Cows, sheep, horses, mink are all affected. Man acquires 
infection from coming in contact with infected material, 
such as hides, wool, horse hair, shaving brushes. The 
spores have been shown to be present in the tusks of ele-
phants and have occasionally been transmitted to man in 
the manufacture of the ivory tips for piano keys. It is an 
old disease. It has caused great economic loss throughout 
the ages. In our own clinic we see about two patients 
with anthrax every year. 
I shall begin my story by telling you that in 1876, a 
young practitioner of medicine in Wollstein, East Prus-
sia, proved that the small sporulating rods found in the 
blood of animals dying of anthrax are the cause of the 
disease. He gave the name Bacillus anthracis to these mi-
croorganisms. The observation was most important, be-
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cause it was the first time that a specific disease was 
shown to be due to a single and characteristic microbe. 
The name of the practitioner was Robert Koch, who later 
discovered the bacteria causing tuberculosis. Organisms 
had been seen in the blood of animals dying of anthrax 
by others before Koch, but their significance was ques-
tioned. In fact, when Koch announced his discovery 
there was still doubt in the minds of some of the French 
scientists concerning their significance, because they had 
been unable to find the organisms in the blood of all ani-
mals dying of anthrax. Moreover, Paul Bert, the great pu-
pil of Claude Bernard, insisted that the disease was due 
to a virus, since he could expose the blood containing 
bacilli to high concentrations of oxygen and destroy the 
bacilli and still produce the disease in experimental ani-
mals. 
At this stage of the controversy, Pasteur stepped in 
and made some experiments. He isolated the anthrax ba-
cillus and cultured it through many generations until he 
felt that the organism was free of any contamination or 
virus. He then inoculated guinea pigs with the bacillus 
and produced anthrax. He was convinced that the organ-
ism was the cause of the disease. It remained, however, 
for him to explain the observations of Julliard and Leplat 
that not all animals dying of anthrax had this bacillus in 
their blood. So Pasteur took a trip to Chartres in south-
em France. There he found a cow dead of anthrax sixteen 
hours, a sheep and a horse dead of the same disease for 
thirty hours. The blood from the cow killed guinea pigs 
following injection, and anthrax bacilli were isolated 
III. A N T I B A C T E R I A L A G E N T S 
from the pigs. The blood from the sheep and the horse 
contained putrefactive organisms but no anthrax bacilli. 
Inoculation of animals with this blood caused death from 
sepsis but not from anthrax. The putrefactive organisms 
had killed off the anthrax bacilli. By cultural methods 
Pasteur succeeded in separating the aerobic anthrax ba-
cilli from the anaerobic putrefactive organisms responsi-
ble for the deaths from sepsis. This was the first demon-
stration that one group of organisms could kill another. 
Pasteur made other observations of importance. One day 
while transferring anthrax bacilli from one flask to an-
other, the media being boiled urine, the culture became 
contaminated with some air organisms. He set the con-
taminated culture aside several days and then examined 
it. To his surprise and consternation, he found that an-
thrax bacilli had disappeared. He drew the logical con-
clusion that the contaminating organisms were respon-
sible for their death. He went further and showed that 
several different organisms were capable of killing an-
thrax bacilli. A few attempts were made to show the an-
tagonistic effect of some organisms upon anthrax by in-
jecting guinea pigs with mixed cultures. The animals did 
not die of anthrax. Some survived; others died of sepsis. 
Here, then, was further proof that the products of the 
growth of one bacterium killed another. 
These observations created great excitement, and for 
some time there was considerable interest in the question 
of bacterial antagonism. Metchnikoff noted that the lac-
tobacilli in the stools decreased sharply or disappeared 
altogether during an attack of dysentery. He reasoned 
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that one organism had killed off the other. He suggested 
that it might be possible to reverse the situation—that is, 
by increasing the numbers of lactobacilli, the pathogenic 
bacteria might be killed off. This idea failed to work out 
when it was tested experimentally. 
There followed a great many observations concerning 
the phenomena of bacterial antagonism. 
Many reports were made, and, naturally, there were 
attempts to apply the rapidly developing theory of bac-
terial antagonism to medical therapeutics. A number of 
bacteria were found to be antagonistic to anthrax bacil-
lus, including B. pyocyaneus, the Friedlander's bacillus, 
and streptococci. Some strains of bacteria were antagonis-
tic to the tubercle bacillus. But attempts to use patho-
genic bacteria to destroy other organisms were not highly 
successful in the treatment of human infections. 
New light was shed on this problem in 1904 when 
Frost found that under certain conditions, typhoid ba-
cilli were destroyed within a few days after they were 
added to soil. However, under conditions that were un-
favorable to the growth of soil bacteria, the typhoid ba-
cilli could persist for months. These observations led 
Frost to conclude that when the soil bacteria were given 
the opportunity to grow and to develop by-products then 
they could kill the typhoid bacillus. In other words, it 
was the metabolic products of the bacteria that killed 
the organisms and not a lack of food for both organisms 
that caused the death of one. 
The next step was an attempt to isolate from the fil-
trates of bacterial cultures the active antibacterial sub-
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stances themselves. The first one to be isolated and used 
was pyocyanase, by Emmerich and Low. They found that 
when the filtrates of cultures of B. pyocyaneus were evap-
orated to one-tenth their original volume, and then 
tested against bacteria in vitro and in vivo, many different 
bacteria were killed. Here was a startling discovery, and 
commercial preparations began to appear on the market 
which for eight or nine years were used to a considerable 
extent in the treatment of a wide variety of infections. 
Unfortunately, the results were inconsistent and ir-
regular, so that pyocyanase was finally given up as a thera-
peutic agent. 
It is perhaps well to pause at this point in our narra-
tive and inquire into the causes for the irregularity in the 
action of pyocyanase. It has been learned that only cer-
tain strains of Ps. aeruginosa produce this substance and, 
moreover, it is now recognized that it must be grown on 
certain media in order that the active product may de-
velop. Further, at least two substances are involved, pyo-
cyanase and pyocyanin. Finally, it has been ascertained 
that these substances are toxic when given parenterally, 
so that they are of no use parenterally. 
Following this period of excitement over the possible 
use of antibacterial agents derived from microbes for 
medical therapeutics there was a lag period in which at-
tention was turned to other agents, such as antitoxins, 
bacterophage, and antiserums. 
Then came the remarkable and outstanding an-
nouncement by Avery and Dubos that they had isolated 
an enzyme from a bacterium that was capable of destroy-
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ing the capsular carbohydrate of the Type II I pneumo-
coccus. Once the coating of sugar had been removed 
from the pneumococcus and digested, the body of the 
pneumococcus could be devoured by the leucocytes of 
the body with the greatest of ease. The story of this dis-
covery is so interesting that I want to tell you about it. 
For several years, Dubos had been interested in the 
problems of cellulose decomposing bacteria of the soil. 
Food substances of plants are derived from cellulose 
decomposition in soil. Microbes decompose cellulose so 
that food products for plants are made available. Each 
year a large quantity of leaves, stalks, and other cellulose 
material falls on every acre of forest land in the United 
States, and each year a large quantity of this cellulose is 
digested by organisms in the soil. Without the activity 
of these organisms, plants and trees would be deprived 
of food. Without the proper food, microbes will also 
weaken and die. It occurred to Dubos that it might be 
possible to find a microbe that could use the vinegar of 
the pneumococcus for food or at least to train an organ-
ism to digest the pneumococcus carbohydrate as a source 
of nourishment. Normally, organisms in soil have enough 
food to live in a state of symbiosis. They compete for 
food and living space. Since there is usually adequate 
space and food, organisms live alongside one another for 
years without lapsing into a destructive state in their 
struggle for survival and existence. 
But Dubos asked the question, What would happen 
to soil microbes if they were starved or if their food sup-
ply was greatly reduced? Would they become cannibal-
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istic or would they merely die of starvation? Could organ-
isms that were starving adapt themselves to a new and 
strange diet and save themselves? This question could be 
answered only by experiment. Therefore, he gathered 
samples of soil and placed them in containers carefully 
protected from the air. With the passage of time, as the 
food supply of the bacteria was used up, the organisms 
began to weaken. Now was the time to determine 
whether any of these organisms could digest the carbo-
hydrate of the Type III pneumococcus. Many of the 
organisms were unable to use this sugar as a source of 
food, but in the containers filled with peat from a New 
Jersey cranberry bog were some microbes that survived. 
They had learned, or were at least able, to utilize the 
new sugar for food. After these organisms were fed a sole 
diet of Pn. polysaccharide, they began to grow fat and 
multiply. Dubos grew them in many generations until 
they were accustomed to the carbohydrate diet. H e then 
isolated from these bacteria the enzyme that was capable 
of digesting the carbohydrate. The substance was effec-
tive in protecting mice against infection, and it was also 
effective in monkeys with Type III pneumonia. I t was 
used with some success in a few patients with T y p e III 
lobar pneumonia, but it had one very serious drawback 
as a therapeutic agent. It caused serious side reactions in 
man. In any event, it was a great fundamental discovery 
and stimulated a tremendous amount of investigation. 
Dubos went further and using somewhat the same tech-
niques developed another substance, known as tyrothri-
cin, an anti-infective agent, derived from an organism in 
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soil, B. brevis. This is a powerful agent that destroys both 
gram-positive and gram-negative bacteria. It can be used 
locally with success for the treatment of infections that 
are of a superficial nature. It cannot be used parenterally 
because of the fact that it is hemolytic for red blood cells 
and causes damage to liver and kidney cells. 
While the search for antibacterial agents was going 
on here in the United States, other students of biology 
and bacteriology in England and elsewhere were busily 
engaged in looking for other agents. 
In 1928, Dr. Alexander Fleming, now Sir Alexander 
Fleming, was making some observations on the degrada-
tion of staphylococci as they aged. He kept his Petri 
dishes on the laboratory bench. He would open them 
from time to time, study the morphology of the aging 
colonies of bacteria, and close the lid once again. One 
day, he noticed that a culture had became contaminated 
with a mold growth. He did not discard the plate as many 
bacteriologists might have done. He examined it care-
fully, and much to his surprise he discovered that in the 
zone around the mold the colonies of bacteria were get-
ting smaller and in some instances had disappeared alto-
gether. This observation excited his interest. He isolated 
the mold, grew it in pure culture, and showed that the 
filtrate from the culture media had the capacity to kill a 
wide variety of microorganisms in high dilution. The ma-
terial was not toxic for leucocytes nor was it toxic for 
small animals. Since the mold was a strain of penicillium, 
he named the active antibacterial substance penicillin. 
Here, then, was a discovery that was made in the labora-
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tory by accident. But it should be remarked that one 
never has an accident of this sort unless he is working 
hard in the laboratory and that one may not appreciate 
the significance of any accident unless his mind is pre-
pared to grasp its significance. 
The discovery of penicillin created somewhat of a 
stir, which did not last very long. One of the reasons for 
the lack of interest in the substance was the great diffi-
culty in producing any quantity of it for experimentation, 
and even then the material was extremely unstable in 
solution. It was about ten years after its discovery that 
Florey, Chain, and their associates at Oxford reopened 
the .study of penicillin. They found that it was extremely 
active against bacteria and nontoxic for mice. With great 
effort, a sufficient amount of penicillin was produced to 
treat six patients successfully. The results were so prom-
ising that the scientists were stimulated to encourage its 
production on a sufficiently large scale to test it thor-
oughly. England was in the lif e-and-death struggle of war, 
so in the summer of 1941, Florey came to this country 
and consulted with the National Research Council and 
the Committee on Medical Research of the Office of 
Scientific Research and Development. A tremendous co-
operative effort was made by the chemical and pharma-
ceutic industry, agencies of government, many hospitals, 
and universities, so that by the spring of 1942, enough 
penicillin was available to treat a single patient. As pro-
duction increased, more and more patients were treated, 
and more and more diseases were found to be brought 
under control by its use. In the spring of 1943, the first 
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wounded men were treated, and by D Day in 1944, there 
was enough penicillin available for our troops and for 
our allies and a moderate amount for civilians. This was 
a remarkable achievement in wartime, since the problems 
of producing penicillin were stupendous. At first, the cost 
was $200 for a million units. Today the same amount 
costs $3.50. This substance derived from the products of 
metabolism of a mold has changed completely the course 
of many diseases. It has saved countless lives and many, 
many days of illness and long suffering. 
One of the most striking features of penicillin is the 
fact that it is effective against a group of bacteria known 
as gram-positive organisms, but has very little effect on 
gram-negative bacteria excepting the gonococcus and the 
meningococcus. It has no effect upon the tubercle bacil-
lus. The search for an antibacterial agent that would con-
trol the gram-negative bacteria like the typhoid bacillus 
and the colon bacillus and the tubercle bacillus went on. 
In 1944, Dr. Selman Waksman and his two associates 
Drs. Bugie and Schatz announced that they had isolated 
a substance called streptomycin that was active against 
both gram-positive and gram-negative bacteria, including 
the tubercle bacillus. This antibiotic was derived from 
one of the Actinomyces that are found in heavily man-
ured soil, but the original strain was isolated from the 
throat of a chicken. Scientists look in strange places for 
all sorts of organisms, and the throat of a chicken may be 
among the strangest. I may add that one of the best 
strains for producing penicillin was isolated from a can-
taloupe in a fruit market in Peoria, Illinois. 
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In any event, it was not long before streptomycin was 
being produced in small amounts and being tested 
against a wide variety of infections, including tuberculo-
sis, tularemia, brucellosis, typhoid fever, influenza bacil-
lus, meningitis, peritonitis, and urinary-tract infections. 
The results have been extremely favorable in many o f 
these infections, and we should note that it is the only 
anti-infective agent derived from microbes that can b e 
used with a positive effect in tuberculosis. While it i s 
not a perfect agent for the treatment of tuberculosis, i t 
is extremely effective in many cases. 
There are other antibacterial agents that are be ing 
investigated, including bacitracin, derived from a strain 
of B. subtilus, and Chloromycetin from a streptomyces. 
W e may expect to hear about many more in the years t o 
come. 
None of these agents are in any way effective against 
virus infections such as influenza vims, poliomyelitis, o r 
the virus of the common cold, and here remains a cha l -
lenge to all of us. It is not too much to hope that s o m e 
day agents may be found which will defeat these in fec -
tions. 
It is truly remarkable that the two agents most w i d e l y 
used, i.e., penicillin and streptomycin, are both effective 
against anthrax, the disease that first directed attention t o 
the subject of bacterial antagonism. They both c o m e 
from the soil. 
What of the future? We have now entered one of t h e 
most stimulating periods in science, that "endless f r o n -
tier." Medical science has come of age in the past fifty 
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years, and tremendous advances are being made every 
year. The spotlight has been turned on a field in medicine 
that was long very dark. There are unlimited opportuni-
ties in medicine and in science for improving the lot of 
mankind. 
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Amniotic fluid, 33, 34 
Anemia, 50 
Anthrax, 18, 57 ff., 67 
Antibacterial agents, 57 ff. 
Antiserum, 44 
Antitoxin, 18 
Arsenic, 16 
Arthralgias, 1 1 
Avery, 61 
Bacilli, diphtheria, 18 
Bacillus anthracis, 57 
Bacillus pyocyaneus, 60, 61" 
Bacitracin, 67 
Bacteremia, 18, 37, 44, 45-46 
Bacteria, 4, 12-13, 19 
Bacteriuria, 43 
Barnwell, 48 
Benadryl, n , 30 
Bernard, Claude, 58 
Bert, Paul, 58 
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Blood, concentration of strepto-
mycin in, 26 
Bronchi, 52 
Bronchiectasis, 14, 46, 47 
Bronchitis, 14, 46 
Bronchopleural fistulae, 19 
Bronchopneumonia, 46 
Bronchopulmonary infections, 3, 35 
Brucella, 36 
Brucellosis, 36-38 
Bugie, 23, 66 
Carriers of diphtheria, 18 
Cerebrospinal fluid, 25, 34, 44, 49 
Chain, 65 
Chartres, 58 
Chloromycetin, 67 
Cholera, 41 
Clostridia, 17 
Clostridial infections, 17 
Cold, common, 67 
Coli-aerogenes, group of bacteria, 14 
Conjunctivae, 3 
Convulsions, 1 1 
Deafness, 31-32, 39 
Dermatitis, contact, 11-12 
Dermatoses, 1 1 
Diarrhea, 41 
Diphtheria, 18 
Dubos, 61, 62, 63 
Dysentery, bacillary, 41 
Ear infections, 41 
Edema of skin and subcutaneous 
tissues, 11 
Embolism, pulmonary, 17 
Emmerich, 61 
Empyema, 19, 33, 47 
Endocarditis, 16-17, 38-39 
England, 64, 65 
Enteric fever, 38 
Eosinophilia, 26, 30 
Epinephrine, 11 
Escherichia coli, 41, 42, 45 
Esophagectomy, 19 
Eye infections, 41 
Feldman, 48 
Fever, 1 1 , 26, 29, 41, 51; enteric, 
38, typhoid, 38 
Finland, 25 
Fleming, Sir Alexander, 64-65 
Florey, 65 
Fractures, compound, 19 
Friedlander's bacillus, 60 
Frost, 60 
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phylactic agent, 1 8 - 1 9 ; preventive 
of streptococcic sore throat, 19; 
combined with streptomycin for 
topical use, 4 0 ; discovery and his-
tory of, 6 4 - 6 5 ; cost of, 6 6 
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Gastroenteritis. 38 
Gastrointestinal tract, 25, 32, 35 
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Gonococcic infections. 9 
Gonorrhea, 9, 18 
Heart failure, 17 
Hemophilus influenzae, 44, 45 , 46 
Hinshaw, 48 
Histamine, 29 
Howes, 40 
Hunter, 38, 39 
Hypopharynx, 52 
Infections, gonococcic, 9; hemolytic 
streptococcic, 9, and streptococcic, 
2, 9; pulmonary, 15-16 
Influenza, 67 
Intestine, tuberculosis of, 53; strep-
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Johnstone, 24 
Joints, pain in, 11 
Julliard, 58 
Kidneys, 25, 34 
Klebsiella pneumoniae, 14, 45.46-47 
Koch, Robert, 58 
Larynx, 52 
Leplat, 58 
Lobectomy, 19 
Low, 61 
Lung abscess, 14, 47 
McDermott, 30, 31, 48 
Mastoiditis, 18 
Mayo clinic, 48 
Meningitis, penicillin in, 13-14, 
streptomycin in, 32, 35; Hemo-
philus influenzae, 44; gram-nega-
tive bacilli causing, 45; with acute 
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Meningococcus, 66 
Metchnikofr, Elie, 59-60 
Murray, 25 
National Research Council, 65 
Nausea, 31 
Necrosis, 51 
Neurologic disturbances, 26, 30-32, 
39 
New Jersey, 63 
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Proteus morganii, 45 
Proteus vulgaris, 42, 45 
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15-16; streptomycin for, 46 ff. 
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42-43 
Pyocyanase, 61 
Pyocyanin, 61 
Pyribenzamine, 1 1 
Pyuria, 53 
Salmonella choleraesuis, 45 
Salmonella infections, 35, 38 
Schatz, 23, 66 
Sepsis, 59 
Serum sickness, 11 
Shigella infections, 41 
Sinuses, 52 
Sinusitis, chronic paranasal, 3 
Skin, 3; edema of, 1 1 ; itching and 
eruptions, 1 1 , 26, 29-30; graft-
ing, 19 
Slough, 40 
Sore throat, streptococcic, 19 
Spinal fluid, 7 
Spirochetal infection, 14 
Sputum, 47, 48 
Staphylococci, 12, 14, 16, 17, 18, 
x 9 
Streptidine, 23 
Streptococci, 9, 12, 13, 14, 16, 18, 
19, 60 
Streptococcus faecalis, 42, 43 
Streptomyces griseus, 23 
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31-32; tinnitus, 32; given subcuta-
neously, intramuscularly, and in-
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Sulfadiazine, 13, 14, 17, 37-38, 44 
Sulfamylon, 40 
Sulfonamides, 16, 17, 39, 41, 45 
Syphilis, 2, 18 
Table 1, 27-28 
Thoracotomy, 19 
Thromboses, 7 
Tinnitus, 32 
Tissues, concentration of penicillin 
in, 7, 8 
Trachea, 52 
Trauma, 46 
Troches, 12 
Tubercle bacillus, 23 
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Typhoid fever, 35, 38 
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Urinary-tract infections, 41-44, 53 
Urine, 25, 34, 42, 43 
Vertigo, 30, 31 
Veterans Administration, 48, 50 
Vibrio, cholera, 4 1 
Virus- infections, 67 
Vomiting, 30 
Waksman, Selman, 23, 24, 66 
Walker, 48 
Weinstein, 9 
Wollstein, East Prussia, 57 
Wound infections, 39-40 
Zintel, 54 
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